Comparison · NCT00760435-31b7bfc3
Infliximab vs Placebo: The Number of Subjects in Each Arm That Have Persistent or Recrudescent Fever 24 Hours After Completion of the Intravenous Immunoglobulin (IVIG) Infusion
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Infliximab vs Placebo: The Number of Subjects in Each Arm That Have Persistent or Recrudescent Fever 24 Hours After Completion of the Intravenous Immunoglobulin (IVIG) Infusion. Trial comparisons, record NCT00760435-31b7bfc3. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00760435-31b7bfc3
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.112 | 0.0638 | 0.19 | wilson | |
| Risk in group 2 | 0.113 | 0.0645 | 0.192 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00116 | -0.0932 | 0.0906 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.99 | 0.45 | 2.17 | log | |
| Odds ratio, group 1 over group 2 | 0.989 | 0.407 | 2.4 | log | |
| Number needed to treat, for one fewer participant with the outcome on Infliximab than on Placebo | 864 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Infliximab | 98 subjects treated with infliximab + IVIG | 11 | 98 | OG000 |
| Group 2 | Placebo | 97 subjects who received placebo + IVIG | 11 | 97 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- The Number of Subjects in Each Arm That Have Persistent or Recrudescent Fever 24 Hours After Completion of the Intravenous Immunoglobulin (IVIG) Infusion
- Description
- Time frame
- 10 weeks
- Population
- 1 subject in the placebo group was removed from the modified ITT analysis (this subject was removed from the study prior to receiving the placebo)
Source ClinicalTrials.gov
Trial
- Title
- Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease
- NCT number
- NCT00760435
- Phases
- PHASE3
- Conditions
- Kawasaki Disease
- Interventions
- Infliximab, Placebo
- Lead sponsor
- University of California, San Diego
- Results first posted
- 2014-11-13
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00760435?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00760435-31b7bfc3